These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33497468)

  • 1. Experience with PlasmaJet™ in debulking surgery in 87 patients with advanced-stage ovarian cancer.
    Volcke A; Van Nieuwenhuysen E; Han S; Salihi R; Van Gorp T; Vergote I
    J Surg Oncol; 2021 Mar; 123(4):1109-1114. PubMed ID: 33497468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Cordeiro Vidal G; Babin G; Querleu D; Guyon F
    Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval debulking surgery following neo-adjuvant chemotherapy for stage IVB ovarian cancer using neutral argon plasma (PlasmaJet™).
    Butler-Manuel S; Lippiatt J; Madhuri TK
    Gynecol Oncol; 2014 Dec; 135(3):622-3. PubMed ID: 25450152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
    Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.
    May T; Comeau R; Sun P; Kotsopoulos J; Narod SA; Rosen B; Ghatage P
    Int J Gynecol Cancer; 2017 May; 27(4):668-674. PubMed ID: 28441250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advanced ovarian cancer: primary debulking (PDS) or neoadjuvant chemotherapy (NACT) - still a debate].
    Segev Y; Gemer O; Auslender R; Lavie O
    Harefuah; 2014 Sep; 153(9):527-31, 558. PubMed ID: 25417489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?
    Zhang X; Yang J; Xiang Y; Pan L; Wu M; Cao D; Yang J
    Int J Gynecol Cancer; 2024 Jan; 34(1):99-105. PubMed ID: 37696647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.
    Bailey CD; Previs R; Fellman BM; Zaid T; Huang M; Brown A; Enbaya A; Balakrishnan N; Broaddus RR; Bodurka DC; Soliman P; Fleming ND; Nick A; Sood AK; Westin SN
    Int J Gynecol Cancer; 2021 Feb; 31(2):232-237. PubMed ID: 33122243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
    Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
    Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal surgical cytoreduction of the upper abdomen and the diaphragm for advanced ovarian cancer using PlasmaJet™ energy.
    Seror J; Bats AS; Habchi H; Lécuru F
    Gynecol Oncol; 2016 Feb; 140(2):372-3. PubMed ID: 26621604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
    Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
    Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer.
    Panuccio E; Leunen K; Van Nieuwenhuysen E; Neven P; Lambrechts S; Vergote I
    Int J Gynecol Cancer; 2016 Oct; 26(8):1521-4. PubMed ID: 27488213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.
    Filippova OT; Chi DS; Long Roche K; Sonoda Y; Zivanovic O; Gardner GJ; Tew WP; O'Cearbhaill R; Sarraf S; Sun SW; Alexander K; Korc-Grodzicki B; Shahrokni A
    Gynecol Oncol; 2019 Jul; 154(1):77-82. PubMed ID: 31078241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
    Drews F; Bertelli G; Lutchman-Singh K
    Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.